Skip to the page

Data / Form D filings / Transcode Therapeutics, Inc.

Transcode Therapeutics, Inc.: Form D filing

Transcode Therapeutics, Inc., a biotechnology company in Boston, MA, filed a Form D with the SEC in 2024. The latest, on December 12, 2024, reports $8 million sold of a $8 million offering to 6 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
6 LIBERTY SQUARE, #2382, Boston, MA, 02109
Phone
(857) 837-3099
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Revenue range
No Revenues
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1829635

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Dec 12, 2024New notice$8,000,000$8,000,0006Dec 2, 2024sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Magda A. MarquetDirector
Erik A. MantingDirector
Thomas A. FitzgeraldExecutive Officer, Director
Philippe A. CalaisDirector

Other biotechnology companies in Massachusetts that filed recently

Every Form D from the week of Dec 9, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Transcode Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.